Agnieszka Wozniak

List of Publications by Year
in descending order

144	5,207	87888	95266
papers	citations	38 h-index	68 g-index

146	146	146	6205
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Mutations in Exons 9 and 13 of KIT Gene Are Rare Events in Gastrointestinal Stromal Tumors. American Journal of Pathology, 2000, 157, 1091-1095.	3.8	299
2	MYC High Level Gene Amplification Is a Distinctive Feature of Angiosarcomas after Irradiation or Chronic Lymphedema. American Journal of Pathology, 2010, 176, 34-39.	3.8	276
3	Risk Criteria and Prognostic Factors for Predicting Recurrences After Resection of Primary Gastrointestinal Stromal Tumor. Annals of Surgical Oncology, 2007, 14, 2018-2027.	1.5	227
4	Molecular pathogenesis of multiple gastrointestinal stromal tumors in NF1 patients. Human Molecular Genetics, 2006, 15, 1015-1023.	2.9	195
5	Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Modern Pathology, 2008, 21, 476-484.	5.5	165
6	A precision therapy against cancers driven by KIT/PDGFRA mutations. Science Translational Medicine, 2017, 9, .	12.4	157
7	Validation of the Joensuu risk criteria for primary resectable gastrointestinal stromal tumour â€“ The impact of tumour rupture on patient outcomes. European Journal of Surgical Oncology, 2011, 37, 890-896.	1.0	153
8	Chromosome Instability Accounts for Reverse Metastatic Outcomes of Pediatric and Adult Synovial Sarcomas. Journal of Clinical Oncology, 2013, 31, 608-615.	1.6	135
9	Crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumours with and without anaplastic lymphoma kinase gene alterations (European Organisation for Research and) Tj ETQq1 1 0.784314 rgBT /Overlock 1 trial. Lancet Respiratory Medicine,the, 2018, 6, 431-441.	10.7	134
10	Tumor Genotype Is an Independent Prognostic Factor in Primary Gastrointestinal Stromal Tumors of Gastric Origin: A European Multicenter Analysis Based on ConticaGIST. Clinical Cancer Research, 2014, 20, 6105-6116.	7.0	129
11	Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumours (GIST): Polish Clinical GIST Registry experience. Annals of Oncology, 2012, 23, 353-360.	1.2	125
12	Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2012, 18, 826-838.	7.0	118
13	Identification of a novel, recurrent MBTD1â€CXorf67 fusion in lowâ€grade endometrial stromal sarcoma. International Journal of Cancer, 2014, 134, 1112-1122.	5.1	117
14	Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, against Gastrointestinal Stromal Tumorâ€“Associated PDGFRAD842V Mutation. Clinical Cancer Research, 2008, 14, 5749-5758.	7.0	116
15	Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial. European Journal of Cancer, 2017, 87, 147-163.	2.8	108
16	Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status. Genes Chromosomes and Cancer, 2007, 46, 261-276.	2.8	106
17	Presence of homozygous KIT exon 11 mutations is strongly associated with malignant clinical behavior in gastrointestinal stromal tumors. Laboratory Investigation, 2007, 87, 1029-1041.	3.7	92
18	Soft Tissue Sarcoma: An Update on Systemic Treatment Options for Patients with Advanced Disease. Oncology Research and Treatment, 2014, 37, 355-362.	1.2	88

#	Article	IF	Citations
19	Coactivated Platelet-Derived Growth Factor Receptor Î± and Epidermal Growth Factor Receptor Are Potential Therapeutic Targets in Intimal Sarcoma. Cancer Research, 2010, 70, 7304-7314.	0.9	80
20	MiR-17-92 and miR-221/222 cluster members target KIT and ETV1 in human gastrointestinal stromal tumours. British Journal of Cancer, 2013, 109, 1625-1635.	6.4	73
21	The DREAM Complex Mediates GIST Cell Quiescence and Is a Novel Therapeutic Target to Enhance Imatinib-Induced Apoptosis. Cancer Research, 2013, 73, 5120-5129.	0.9	72
22	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. European Urology, 2018, 74, 474-480.	1.9	72
23	The Neurofibromatosis Type 2 Gene Is Mutated in Perineurial Cell Tumors. American Journal of Pathology, 2001, 158, 1223-1229.	3.8	70
24	Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 â€˜CREATEâ€™. Annals of Oncology, 2017, 28, 3000-3008.	1.2	70
25	Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 â€˜CREATEâ€™. Annals of Oncology, 2018, 29, 758-765.	1.2	67
26	A Potent Combination of the Novel PI3K Inhibitor, GDC-0941, with Imatinib in Gastrointestinal Stromal Tumor Xenografts: Long-Lasting Responses after Treatment Withdrawal. Clinical Cancer Research, 2013, 19, 620-630.	7.0	64
27	Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. Clinical Cancer Research, 2019, 25, 609-618.	7.0	63
28	The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study. BMC Cancer, 2012, 12, 107.	2.6	62
29	Rearrangement of theCOL12A1andCOL4A5genes in subungual exostosis: molecular cytogenetic delineation of the tumor-specific translocationt(X;6)(q13-14;q22). International Journal of Cancer, 2006, 118, 1972-1976.	5.1	53
30	High Efficacy of Panobinostat Towards Human Gastrointestinal Stromal Tumors in a Xenograft Mouse Model. Clinical Cancer Research, 2009, 15, 4066-4076.	7.0	53
31	The HSP90 Inhibitor, AT13387, Is Effective against Imatinib-Sensitive and -Resistant Gastrointestinal Stromal Tumor Models. Molecular Cancer Therapeutics, 2012, 11, 1799-1808.	4.1	53
32	Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opinion on Pharmacotherapy, 2008, 9, 1609-1618.	1.8	50
33	The Novel HSP90 Inhibitor, IPI-493, Is Highly Effective in Human Gastrostrointestinal Stromal Tumor Xenografts Carrying Heterogeneous KIT Mutations. Clinical Cancer Research, 2011, 17, 5604-5614.	7.0	48
34	Defining pseudoprogression in glioblastoma multiforme. European Journal of Neurology, 2013, 20, 1335-1341.	3.3	48
35	Clinical utility of the new American Joint Committee on Cancer staging system for gastrointestinal stromal tumors. Cancer, 2011, 117, 4916-4924.	4.1	47
36	Phosphoinositide 3-Kinase Inhibitors Combined with Imatinib in Patient-Derived Xenograft Models of Gastrointestinal Stromal Tumors: Rationale and Efficacy. Clinical Cancer Research, 2014, 20, 6071-6082.	7.0	45

#	Article	IF	Citations
37	The Heat Shock Protein 90 Inhibitor IPI-504 Induces KIT Degradation, Tumor Shrinkage, and Cell Proliferation Arrest in Xenograft Models of Gastrointestinal Stromal Tumors. Molecular Cancer Therapeutics, 2011, 10, 1897-1908.	4.1	43
38	Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 â€˜CaboGISTâ€™. European Journal of Cancer, 2020, 134, 62-74.	2.8	42
39	Unbiased Compound Screening Identifies Unexpected Drug Sensitivities and Novel Treatment Options for Gastrointestinal Stromal Tumors. Cancer Research, 2014, 74, 1200-1213.	0.9	40
40	Deep sequencing reveals microRNAs predictive of antiangiogenic drug response. JCI Insight, 2016, 1, e86051.	5.0	39
41	Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft Models. Translational Oncology, 2014, 7, 665-671.	3.7	38
42	Advances in Molecular Characterization and Targeted Therapy in Dermatofibrosarcoma Protuberans. Sarcoma, 2011, 2011, 1-6.	1.3	37
43	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clinical Genitourinary Cancer, 2018, 16, e605-e612.	1.9	37
44	Primary myxoid mesenchymal tumour with intracranial location: report of a case with a <scp>EWSR</scp>1â€“<scp>ATF</scp>1 fusion. Histopathology, 2018, 72, 880-883.	2.9	37
45	Posttransplant Epstein-Barr Virus-Associated Myogenic Tumors: Case Report and Review of the Literature. American Journal of Transplantation, 2008, 8, 253-258.	4.7	36
46	Frequent activation of EGFR in advanced chordomas. Clinical Sarcoma Research, 2011, 1, 4.	2.3	36
47	SS18-SSXâ€“Dependent YAP/TAZ Signaling in Synovial Sarcoma. Clinical Cancer Research, 2019, 25, 3718-3731.	7.0	36
48	KIT overexpression and amplification in gastrointestinal stromal tumors (GISTs). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2005, 1741, 165-172.	3.8	35
49	The tyrosine kinase inhibitor crizotinib does not have clinically meaningful activity in heavily pre-treated patients with advanced alveolar rhabdomyosarcoma with FOXO rearrangement: European Organisation for Research and Treatment of Cancer phase 2 trial 90101 â€˜CREATEâ€™. European Journal of Cancer, 2018, 94, 156-167.	2.8	35
50	Loss of heterozygosity on chromosome 22q in gastrointestinal stromal tumors (GISTs): a study on 50 cases. Laboratory Investigation, 2005, 85, 237-247.	3.7	34
51	Metastatic potential is determined early in synovial sarcoma development and reflected by tumor molecular features. International Journal of Biochemistry and Cell Biology, 2014, 53, 505-513.	2.8	34
52	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	1.9	34
53	Predictive factors for long-term effects of imatinib therapy in patients with inoperable/metastatic CD117(+) gastrointestinal stromal tumors (GISTs). Journal of Cancer Research and Clinical Oncology, 2007, 133, 589-597.	2.5	31
54	Biology and management of clear cell sarcoma: state of the art and future perspectives. Expert Review of Anticancer Therapy, 2016, 16, 839-845.	2.4	31

#	Article	IF	Citations
55	Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification. Clinical and Translational Oncology, 2020, 22, 546-554.	2.4	31
56	Rectal gastrointestinal stromal tumors associated with a novel germline KIT mutation. International Journal of Cancer, 2008, 122, 2160-2164.	5.1	30
57	Cabozantinib Is Active against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations. Molecular Cancer Therapeutics, 2016, 15, 2845-2852.	4.1	30
58	Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncology, 2007, 3, 381-392.	2.4	27
59	Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors. Modern Pathology, 2014, 27, 1510-1520.	5.5	27
60	Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE. European Journal of Cancer, 2021, 156, 12-23.	2.8	26
61	Characterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors. Clinical Sarcoma Research, 2014, 4, 10.	2.3	24
62	Establishment and Characterization of Histologically and Molecularly Stable Soft-tissue Sarcoma Xenograft Models for Biological Studies and Preclinical Drug Testing. Molecular Cancer Therapeutics, 2019, 18, 1168-1178.	4.1	23
63	Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. European Journal of Cancer, 2017, 75, 33-40.	2.8	22
64	Clinical Presentation, Pathological Features and Natural Course of Metastatic Uveal Melanoma, an Orphan and Commonly Fatal Disease. Oncology, 2014, 86, 185-189.	1.9	21
65	Expression and significance of HER family receptors in neuroblastic tumors. Clinical and Experimental Metastasis, 2011, 28, 271-282.	3.3	20
66	What are the current outcomes of advanced gastrointestinal stromal tumors: who are the long-term survivors treated initially with imatinib?. Medical Oncology, 2013, 30, 765.	2.5	20
67	Changes in expression of serine proteases HtrA1 and HtrA2 during estrogen-induced oxidative stress and nephrocarcinogenesis in male Syrian hamster.. Acta Biochimica Polonica, 2008, 55, 9-20.	0.5	20
68	Malignant Ectomesenchymoma: Genetic Profile Reflects Rhabdomyosarcomatous Differentiation. Diagnostic Molecular Pathology, 2007, 16, 243-248.	2.1	19
69	New targets and therapies for gastrointestinal stromal tumors. Expert Review of Anticancer Therapy, 2017, 17, 1117-1129.	2.4	18
70	Abstract 1460: Establishment and characterization of a panel of patient-derived soft tissue sarcoma (STS) xenograft models for in vivo testing of novel therapeutic approaches. Cancer Research, 2015, 75, 1460-1460.	0.9	17
71	A unique occurrence of a cerebral atypical teratoid/rhabdoid tumor in an infant and a spinal canal primitive neuroectodermal tumor in her father. Journal of Neuro-Oncology, 2003, 61, 219-225.	2.9	16
72	A girl with duplication 9q34 syndrome. American Journal of Medical Genetics, Part A, 2007, 143A, 2019-2023.	1.2	16

#	Article	IF	Citations
73	Implications of Mutational Analysis for the Management of Patients With Gastrointestinal Stromal Tumors and the Application of Targeted Therapies. Cancer Investigation, 2010, 28, 839-848.	1.3	16
74	In Vivo Antitumoral Efficacy of PhAc-ALGP-Doxorubicin, an Enzyme-Activated Doxorubicin Prodrug, in Patient-Derived Soft Tissue Sarcoma Xenograft Models. Molecular Cancer Therapeutics, 2017, 16, 1566-1575.	4.1	15
75	Promoting role of cholecystokinin 2 receptor (CCK2R) in gastrointestinal stromal tumour pathogenesis. Journal of Pathology, 2012, 228, 565-574.	4.5	14
76	Therapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models. Translational Oncology, 2015, 8, 112-118.	3.7	14
77	Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach. Oncology Research and Treatment, 2016, 39, 811-816.	1.2	14
78	Anagrelide for Gastrointestinal Stromal Tumor. Clinical Cancer Research, 2019, 25, 1676-1687.	7.0	14
79	Prognostic significance of HER2 expression in neuroblastic tumors. Modern Pathology, 2010, 23, 1261-1268.	5.5	13
80	Retrospective Analysis of Outcome of Patients with Metastatic Leiomyosarcoma in a Tertiary Referral Center. Oncology Research and Treatment, 2018, 41, 206-213.	1.2	13
81	PLX9486 shows anti-tumor efficacy in patient-derived, tyrosine kinase inhibitor-resistant KIT-mutant xenograft models of gastrointestinal stromal tumors. Clinical and Experimental Medicine, 2019, 19, 201-210.	3.6	13
82	Periventricular heterotopia in a boy with interstitial deletion of chromosome 4p. European Journal of Medical Genetics, 2008, 51, 165-171.	1.3	12
83	Comprehensive Molecular Analysis of Inflammatory Myofibroblastic Tumors Reveals Diverse Genomic Landscape and Potential Predictive Markers for Response to Crizotinib. Clinical Cancer Research, 2021, 27, 6737-6748.	7.0	12
84	Polymorphisms in the Von Hippelâ€“Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2018, 16, 266-273.	1.9	11
85	Retrospective Analysis of Patients with Advanced Liposarcoma in a Tertiary Referral Center. Oncology Research and Treatment, 2019, 42, 396-404.	1.2	10
86	Randomised phase 2 study comparing the efficacy and safety of the oral tyrosine kinase inhibitor nintedanib with single agent ifosfamide in patients with advanced, inoperable, metastatic soft tissue sarcoma after failure of first-line chemotherapy: EORTC-1506-STBSG â€œANITAâ€• European Journal of Cancer, 2021, 152, 26-40.	2.8	10
87	Plocabulin, a novel tubulin inhibitor, has potent antitumor activity in patient-derived xenograft models of gastrointestinal stromal tumors. Translational Oncology, 2020, 13, 100832.	3.7	9
88	Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 â€œCREATEâ€•Trial. Cancers, 2021, 13, 6057.	3.7	9
89	Machine learning for rhabdomyosarcoma histopathology. Modern Pathology, 2022, 35, 1193-1203.	5.5	9
90	Differential antitumor activity of compounds targeting the ubiquitin-proteasome machinery in gastrointestinal stromal tumor (GIST) cells. Scientific Reports, 2020, 10, 5178.	3.3	8

#	Article	IF	Citations
91	Partial trisomy of distal 5q and partial monosomy of Xp as a result of mating between two translocation carriers: a female with a balanced translocation t(X;5)(p11;q31) and a male with a der(13;14)(q10;q10)â€"a case report and a family study. Annales De GÃ©nÃ©tique, 2002, 45, 143-146.	0.4	7
92	Assessment of the platelet-derived growth factor receptor alpha antibody olaratumab in a panel of patient-derived soft tissue sarcoma xenografts. BMC Cancer, 2019, 19, 724.	2.6	6
93	Pan-Cancer Detection and Typing by Mining Patterns in Large Genome-Wide Cell-Free DNA Sequencing Datasets. Clinical Chemistry, 2022, 68, 1164-1176.	3.2	6
94	Complex tumor-specific t(X;18) in seven synovial sarcoma tumors. Cancer Genetics and Cytogenetics, 2009, 189, 118-121.	1.0	5
95	Retroperitoneal Dedifferentiated Liposarcomas with Production of Î²-Human Chorionic Gonadotropin â€“ a Distinct Sarcoma Entity?. Onkologie, 2011, 34, 122-125.	0.8	5
96	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PLoS ONE, 2020, 15, e0238809.	2.5	5
97	Molecular Biomarkers of Response to Eribulin in Patients with Leiomyosarcoma. Clinical Cancer Research, 2021, 27, 3106-3115.	7.0	5
98	Establishment of an Academic Tissue Microarray Platform as a Tool for Soft Tissue Sarcoma Research. Sarcoma, 2021, 2021, 1-12.	1.3	4
99	A Robust Method for Sample Preparation of Gastrointestinal Stromal Tumour for LC/MS Untargeted Metabolomics. Metabolites, 2021, 11, 554.	2.9	4
100	Abstract CT006: Crizotinib achieves objective responses and long-lasting disease control in patients (pts) with metastatic papillary renal cell carcinoma type 1 (PRCC1) with somaticMETmutations. EORTC phase II trial 90101 â€œCREATEâ€•, 2016, , .		4
101	Activity of crizotinib (C) in patients (pts) with clear cell sarcoma (CCSA) in EORTC phase II trial 90101 "CREATE".. Journal of Clinical Oncology, 2015, 33, 10542-10542.	1.6	4
102	Efficacy of BLU-285, a novel, potent inhibitor of Exon 17 Mutant KIT and PDGFRA D842V, in patient-derived xenograft model of gastrointestinal stromal tumor (GIST).. Journal of Clinical Oncology, 2016, 34, 11030-11030.	1.6	4
103	Long-Term Outcomes in Clear-Cell Renal Cell Carcinoma Patients Treated with Complete Metastasectomy. Kidney Cancer, 2020, 4, 177-183.	0.4	4
104	PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index. Molecular Cancer Therapeutics, 2022, 21, 568-581.	4.1	4
105	In Vivo Evaluation of Fibroblast Growth Factor Receptor Inhibition in Mouse Xenograft Models of Gastrointestinal Stromal Tumor. Biomedicines, 2022, 10, 1135.	3.2	4
106	Abstract 775: Anti-tumor effects of dovitinib, a multi-target kinase inhibitor, in patient-derived gastrointestinal stromal tumor (GIST) xenograft models. , 2015, , .		3
107	Enapotamab Vedotin, an AXL-Specific Antibody-Drug Conjugate, Demonstrates Antitumor Efficacy in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. International Journal of Molecular Sciences, 2022, 23, 7493.	4.1	3
108	Volatile organic compounds in gastrointestinal stromal tumour tissue originating from patient-derived xenografts. Journal of Breath Research, 2017, 11, 037101.	3.0	2

#	Article	IF	Citations
109	Efficacy of a phosphoinositol 3 kinase (PI3K) inhibitor in gastrointestinal stromal tumor (GIST) models.. Journal of Clinical Oncology, 2012, 30, 10030-10030.	1.6	2
110	Identification of potential molecular biomarkers for response of soft tissue sarcoma to eribulin: Translational results of EORTC trial 62052.. Journal of Clinical Oncology, 2013, 31, 10573-10573.	1.6	2
111	Loss of heterozygosity in 73 human thyroid tumors. Neuroendocrinology Letters, 2005, 26, 521-5.	0.2	2
112	Correlation of Immunological and Molecular Profiles with Response to Crizotinib in Alveolar Soft Part Sarcoma: An Exploratory Study Related to the EORTC 90101 â€œCREATEâ€•Trial. International Journal of Molecular Sciences, 2022, 23, 5689.	4.1	2
113	Targeted Therapy in Gastrointestinal Stromal Tumors. Current Clinical Pathology, 2015, , 163-196.	0.0	1
114	Improvement of existing risk classifications in primary gastrointestinal stromal tumors (GIST).. Journal of Clinical Oncology, 2014, 32, 10517-10517.	1.6	1
115	Efficacy of an enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenografts.. Journal of Clinical Oncology, 2015, 33, e13539-e13539.	1.6	1
116	Effect of crizotinib on disease control in patient with advanced papillary renal cell carcinoma type 1 with MET mutations or amplification: Final results of EORTC 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 580-580.	1.6	1
117	Abstract 5353: Efficacy of an innovative, enzyme-activated doxorubicin prodrug in patient-derived dedifferentiated liposarcoma and synovial sarcoma xenograft models. , 2015, , .		1
118	Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.. Journal of Clinical Oncology, 2018, 36, 11540-11540.	1.6	1
119	Abstract CT045: Prospective precision medicine trial of crizotinib (C) in patients (pts) with advanced, inoperable inflammatory myofibroblastic tumor (IMFT) with and without ALK alterations: EORTC phase II study 90101 "CREATE". Cancer Research, 2018, 78, CT045-CT045.	0.9	1
120	Abstract 3840: Plocabulin, a tubulin inhibitor, presents antitumor activity in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor (GIST). , 2018, , .		1
121	Enhanced Antitumor Efficacy of PhAc-ALGP-Dox, an Enzyme-Activated Doxorubicin Prodrug, in a Panel of THOP1-Expressing Patient-Derived Xenografts of Soft Tissue Sarcoma. Biomedicines, 2022, 10, 862.	3.2	1
122	Plocabulin, a Novel Tubulin Inhibitor, Has Potent Antitumour Activity in Patient-Derived Xenograft Models of Soft Tissue Sarcoma. International Journal of Molecular Sciences, 2022, 23, 7454.	4.1	1
123	Title is missing!. Journal of Neuro-Oncology, 2003, 64, 284-284.	2.9	0
124	Neuroblastic Tumors â€“ Status and Role of HER Family Receptors. Pediatric Cancer, 2012, , 89-98.	0.0	0
125	Anti-tumor effects of dovitinib in patient-derived gastrointestinal stromal tumor (GIST) xenograft models.. Journal of Clinical Oncology, 2015, 33, 10532-10532.	1.6	0
126	Abstract 1461: A panel of patient derived gastrointestinal stromal tumors (GIST) xenograft models for in vivo preclinical drug testing. , 2015, , .		0

#	Article	IF	Citations
127	Abstract 774: Cabozantinib, a multi-target receptor tyrosine kinase inhibitor, decreases tumor growth and angiogenesis in a patient-derived dedifferentiated liposarcoma xenograft. , 2015, , .		0
128	Single-center experience with advanced liposarcoma (LPS): Overall survival (OS), prognostic factors and chemotherapy outcome.. Journal of Clinical Oncology, 2016, 34, e22521-e22521.	1.6	0
129	Single-center experience with metastatic leiomyosarcoma: Survival, prognostic factors and outcome of chemotherapy.. Journal of Clinical Oncology, 2016, 34, e22531-e22531.	1.6	0
130	Abstract 5197: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS): a preclinical platform for early drug testing. , 2016, , .		0
131	Abstract 2081: Robust activity of BLU-285, a potent and highly selective inhibitor of mutant KIT and PDGFRÎ±, in patient-derived xenograft (PDX) models of gastrointestinal stromal tumor (GIST). , 2017, , .		0
132	Abstract 4811: XenoSarc: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS), an update on a preclinical platform for early drug testing. , 2017, , .		0
133	Abstract 1031: XenoSarc: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS)â€”an update on a preclinical platform for early drug testing. , 2018, , .		0
134	Abstract 388: SS18-SSX modulates YAP/TAZ-TEAD transcriptional activity in synovial sarcoma. , 2019, , .		0
135	Abstract 4280: Potential molecular biomarkers of response to eribulin in patients with leiomyosarcoma. , 2020, , .		0
136	Abstract 1676: Plocabulin, a novel tubulin inhibitor, has antitumor activity in various patient-derived xenograft models of soft tissue sarcoma. , 2020, , .		0
137	Abstract 5438: Establishment of an academic tissue microarray platform as an efficient tool for soft tissue sarcoma research. , 2020, , .		0
138	Abstract 1117: XenoSarc: Patient-derived xenograft (PDX) models of soft tissue sarcoma (STS) and their histopathological and molecular characterization. , 2020, , .		0
139	Abstract 794: Molecular analysis of archival inflammatory myofibroblastic tumor tissue samples from EORTC 90101 â€œCREATEâ€•and correlation with response to crizotinib. , 2020, , .		0
140	Abstract 3191: Detection of molecular drivers in inflammatory myofibroblastic tumor: study on archival tissue from EORTC 90101 â€œCREATEâ€•phase II clinical trial. , 2020, , .		0
141	Title is missing!. , 2020, 15, e0238809.		0
142	Title is missing!. , 2020, 15, e0238809.		0
143	Title is missing!. , 2020, 15, e0238809.		0
144	Title is missing!. , 2020, 15, e0238809.		0